Email updates

Keep up to date with the latest news and content from BMC Dermatology and BioMed Central.

Open Access Highly Accessed Case report

Treatment of disseminated granuloma annulare with fumaric acid esters

Alexander Kreuter, Thilo Gambichler*, Peter Altmeyer and Norbert H Brockmeyer

Author Affiliations

Department of Dermatology, Ruhr-University Bochum, Gudrunstrasse 56, 44791 Bochum, Germany

For all author emails, please log on.

BMC Dermatology 2002, 2:5  doi:10.1186/1471-5945-2-5


The electronic version of this article is the complete one and can be found online at: http://www.biomedcentral.com/1471-5945/2/5


Received:19 December 2001
Accepted:19 March 2002
Published:19 March 2002

© 2002 Kreuter et al; licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL.

Abstract

Background

Granuloma annulare is a granulomatous disease of unknown etiology. Various therapies have been tried in disseminated granuloma annulare (DGA), including corticosteroids, several variants of psoralen plus ultraviolet-A radiation, ultraviolet- A1 radiation, systemic retinoids, and dapsone, with variable success. We report a patient with recalcitrant DGA who was treated with fumaric acid esters (FAE).

Case presentation

A 40-year old Caucasian woman presented with a 25-year history of recalcitrant DGA. On both legs and the abdomen there were erythematous annular plaques. She was treated with FAE in tablet form using two formulations differing in strength (low strength tablets: 30 mg dimethylfumarate, 67 mg monoethylfumarate Ca salt, 5 mg monoethylfumarate Mg salt, 3 mg monoethylfumarate Zn salt; high strength tablets: 120 mg dimethylfumarate, 87 mg monoethylfumarate Ca salt, 5 mg monoethylfumarate Mg salt, 3 mg monoethylfumarate Zn salt). After three-month therapy, an almost complete clearance of skin lesions was achieved. With the exception of temporary lymphopenia, no adverse effects were observed. The patient remained in remission during a six-month follow up period.

Conclusions

Our observation has demonstrated that FAE is a potentially beneficial therapeutic option for patients with recalcitrant DGA. However controlled trials are necessary to fully explore the efficacy, optimal dosage, and safety of FAE in the management of DGA.

Background

Granuloma annulare is a granulomatous disease of unknown etiology. Disseminated granuloma annulare (DGA) is characterized by a chronic course of disease and frequent association with systemic disorders such as diabetes mellitus. Although spontaneous resolution can occur in some cases various therapies have been tried in DGA, including corticosteroids, several variants of psoralen plus ultraviolet-A radiation, ultraviolet- A1 radiation, systemic retinoids, and dapsone, with variable success [1-5]. We report a patient with recalcitrant DGA who was treated with fumaric acid esters (FAE).

Case presentation

A 40-year old Caucasian woman presented with a 25-year history of DGA on both legs. Since one year, she also had lesions on the abdomen. Previous treatments with various therapeutic modalities (e.g., corticosteroids, dapsone, and bath psoralen plus ultraviolet-A radiation) were ineffective. On examination, she had erythematous annular plaques on the abdomen and on both legs (Fig. 1). Histopathologic examination of a punch biopsy specimen from the left leg revealed a normal epidermis. Below the epidermis there was mild collagen degeneration surrounded by palisading inflammatory cells. The infiltrates consisted of a mixture of monocytes, histiocytes, and occasional giant cells. These findings were consistent with the diagnosis of DGA. Complete work-up did not reveal evidence of malignancies, infections, and internal diseases such as diabetes mellitus.

thumbnailFigure 1. Long-standing disseminated granuloma annulare on the left leg.

Since the disease had been recalcitrant to various conventional therapies, we decided to start oral treatment with fumaric acid esters. The patient was treated with FAE in tablet form using two formulations differing in strength (low strength tablets: 30 mg dimethylfumarate, 67 mg monoethylfumarate Ca salt, 5 mg monoethylfumarate Mg salt, 3 mg monoethylfumarate Zn salt; high strength tablets: 120 mg dimethylfumarate, 87 mg monoethylfumarate Ca salt, 5 mg monoethylfumarate Mg salt, 3 mg monoethylfumarate Zn salt), supplied as Fumaderm® initial and Fumaderm® (Fumedica GmbH, Herne, Germany) [6]. Dosage of FAE was performed according to the standard therapy regimen for psoriasis patients displayed in Table 1. After two months, a complete clearance of skin lesions on the abdomen was achieved. Long-standing lesions on the legs improved after three-month therapy (Fig. 2). No subjective side effects were observed during treatment. Regular laboratory investigations, including differentiate blood count and kidney function, did not revealed abnormal findings during therapy, with the exception of slight lymphocytopenia. After discontinuation of treatment with FAE the patient remained in remission during a six-month follow up period.

thumbnailFigure 2. Almost complete clearance of disseminated granuloma annulare after 3 months of therapy with fumaric acid esters.

Table 1. Dosage schedule of fumaric acid esters used for the presented patient with disseminated granuloma annulare

Discussion

FAE has been shown to be an effective therapy option in patients with severe psoriasis vulgaris [6,7]. During therapy with fumaric acid a persistent decrease in the lymphocyte count and stimulation of TH2 cytokine responses have been observed. Since psoriasis is regarded as a TH1-type inflammatory disorder, the immunomodulation away from the TH1 cytokine IFN-γ to the TH2 cytokine IL-10 may lead to improvement of the disease. Furthermore the anipsoriatic activity of fumaric acid may also be mediated by diminishing proinflammatory cytokine overexpression and the antigen-presenting capacity of monocytes and macrophages [8,9].

It has been reported that FAE induce apoptosis in human dentritic cells as well as keratinocytes [10]. Histopathologically, localized granuloma as well as DGA are characterized by lymphohistiocytic and monocytic infiltrates that form palisading granulomas with central necrobiotic changes. In a recent study, numerous apoptotic macrophages have been observed within the necrobiotic areas [11]. A popular view concerning pathogenesis holds that granuloma annulare is based on a delayed-type hypersensitivity reaction to as yet undefined cutaneous antigens. Phototherapy (e.g., psoralen plus ultraviolet-A radiation, ultraviolet- A1 radiation) is effective in DGA and is known to suppress delayed hypersensitivity responses in the skin [3-5]. Previous findings suggest that a T cell-mediated immune response producing cytokines may be the dominant pathogenic factor in granuloma annulare [12]. Thus the efficacy of FAE in DGA may be mediate by similar immunomodulatory mechanisms that are observed in the treatment of psoriasis. Notably it has been observed that treatment with FAE was also effective in cutaneous sarcoidosis and necrobiosis lipoidica which are closely related to granuloma annulare U. Nowack, MD, and T. Gambichler, MD; unpublished data). Schulze-Dirks and Petzoldt [13] reported a female with a one-year history of DGA which resolved after six-week treatment of FAE. Since our patient had long-standing DGA, which was recalcitrant to potentially helpful therapeutic modalities, we do not consider that the therapeutic effect was due to spontaneous resolution. It has been demonstrated that FAE are well tolerated drugs suitable for long-term management (> 6 months) in psoriasis. Subjective adverse effects such as flushing and gastrointestinal symptoms are frequently observed. Relative lymphocytopenia is the most frequent laboratory finding in long-term users. Therefore therapy with FAE should only be performed under controlled conditions [14]. FAE are a potentially beneficial therapeutic option for patients with recalcitrant DGA. Controlled trials are however necessary to fully explore the efficacy, optimal dosage, and safety of FAE in the treatment of DGA.

List of abbreviations

DGA: disseminated granuloma annulare

FAE: fumaric acid esters

Competing interests

None declared

References

  1. Dabski K, Winkelmann RK: Generalized granuloma annulare: Histopathology and immunology. Systematic review of 100 cases and comparison with localized granuloma annulare.

    J Am Acad Dermatol. 1989, 20:39-47. PubMed Abstract OpenURL

  2. Smith D, Downie JB, DiCostanzo D: Granuloma annulare.

    Int J Dermatol. 1997, 36:326-333. PubMed Abstract | Publisher Full Text OpenURL

  3. Muchenberger S, Schöpf E, Simon JC: Phototherapy with UV-A-1 for generalized granuloma annulare.

    Arch Dermatol. 1997, 133:1605. PubMed Abstract OpenURL

  4. Salomon N, Walchner M, Messer G, Plewig G, Röcken M: Bath-PUVA therapy of granuloma annulare.

    Hautarzt 1999, 50:275-279. PubMed Abstract | Publisher Full Text OpenURL

  5. Gambichler T, Menzel S: Cream PUVA in granuloma annulare.

    Z Dermatol. 1999, 185:124-127. OpenURL

  6. Mrowietz U, Christophers E, Altmeyer P: Treatment of severe psoriasis with fumaric acid esters: scientific background and guidelines for therapeutic use.

    Br J Dermatol. 1999, 141:424-429. PubMed Abstract | Publisher Full Text OpenURL

  7. Altmeyer P, Matthes U, Pawlak F, Hoffmann K, Frosch PJ, Ruppert P, et al.: Antipsoriatic effect of fumaric acid derivates.

    J Am Acad Dermatol. 1994, 30:977-981. PubMed Abstract OpenURL

  8. De Jong R, Bezemer AC, Zomerdijk PL, van de Pouw-Kraan, Ottenhoff HM, Nibbering PH: Selective stimulation of T helper 2 cytokine responses by anti-psoriasis agent monomethylfumarate.

    Eur J Immunol. 1996, 26:2067-2074. PubMed Abstract OpenURL

  9. Asadullah K, Schmid H, Friedrich M, Randow F, Volk H, Sterry W, et al.: Influence of monomethylfumarate on monocytic cytokine formation – explanation for adverse and therapeutic effects in psoriasis.

    Arch Dermatol Res. 1997, 289:623-630. PubMed Abstract | Publisher Full Text OpenURL

  10. Zhu K, Mrowietz U: Inhibition of dentritic cell differentiation by fumaric acid esters.

    J Invest Dermatol 2001, 116:203-208. PubMed Abstract | Publisher Full Text OpenURL

  11. Fayyazi A, Schweyer S, Eichmeyer B, Herms J, Hemmerlein B, Radzun HJ, Berger H: Expression of IFNgamma, coexpression of TNFalpha and matrix metalloproteinases and apoptosis of T lymphocytes and macrophages in granuloma annulare.

    Arch Dermatol Res 2000, 292:384-390. PubMed Abstract | Publisher Full Text OpenURL

  12. Buechner SA, Winkelmami RK, Banks PM: Identification of T-cell subpopulations in granuloma annulare.

    Arch Dermatol. 1983, 119:125-128. PubMed Abstract | Publisher Full Text OpenURL

  13. Schulze-Dirks A, Petzoldt D: Disseminated granuloma annulare – successful therapy with fumaric acid esters.

    Hautarzt 2001, 52:228-230. PubMed Abstract | Publisher Full Text OpenURL

  14. Thio HB, van der Schroeff JG, Nugteren-Huying WM, Vermeer BJ: Long-term systemic therapy with dimethylfumarate and monoethylfumarate (Fumaderm®) in psoriasis.

    J Eur Acad Dermatol Venereol 1995, 4:35-40. Publisher Full Text OpenURL

Pre-publication history

The pre-publication history for this paper can be accessed here:

http://www.biomedcentral.com/1471-5945/2/5/prepub